Armed with encouraging data from clinical trials, thoracic medical oncologist Dr. Jacob Sands walks us through the lung cancer screening technology that has the potential to save about 48,000 lives per year.

RET mutations or rearrangements have been observed in many cancers—including non-small cell lung cancer. But what does this genetic marker mean for our patients and the treatment landscape as a whole? That’s the question Dr. Edward Kim is here to answer.

RET mutations or rearrangements have been observed in many cancers—including non-small cell lung cancer. But what does this genetic marker mean for our patients and the treatment landscape as a whole? That’s the question Dr. Edward Kim is here to answer.

Although only a small percentage of patients with non-small cell lung cancer have a genetic mutation involving the RET gene, it’s still essential that we know how this specific mutation impacts our diagnostic and treatment approach. That’s why we’re taking a look at this through the lens of a real-world patient case from Dr. Michael Shafique’s experience as an Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center in Tampa, Florida.

Here to explain how our refined understandings of driver mutations, immune properties, and tumor microenvironments have changed the way we think about combination therapies, their benefits and limitations, and what’s on the horizon is Dr. Jonathan Riess, Associate Professor of Oncology and Hematology at the UC Davis Medical Center.

Testing for the biomarker PD-L1 can offer clinicians direction for their treatment approach to non-small cell lung cancer, and here to offer insights on therapeutic approaches for patients with high PD-L1 expression is Dr. Michael Shafique, Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center in Tampa, Florida.

To find out more about the structure, results, and implications of the REVEL trial, we spoke with Dr. Michael Shafique, Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center in Tampa, Florida.

Tune in as Dr. Michael Shafique from the Moffitt Cancer Center explains the KEYNOTE-189 clinical trial, which investigated whether the addition of pembrolizumab to standard of care platinum-based chemotherapy would provide some survival benefit to patients with non-small cell lung cancer.

Although only a small percentage of patients with non-small cell lung cancer have a genetic mutation involving the RET gene, it’s still essential that we know how this specific mutation impacts our diagnostic and treatment approach. That’s why we’re taking a look at this through the lens of a real-world patient case from Dr. Michael Shafique’s experience as an Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center in Tampa, Florida.

Early diagnosis of non-small cell lung cancer (NSCLC) can increase patients’ rate of survival, and primary care practitioners play an important role in this since they’re oftentimes on the frontlines of care. Here to discuss with Dr. John Russell how primary care practitioners like himself can expedite getting patients with NSCLC to treatment is oncologist Dr. Mark Sundermeyer.

Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.